Evidence map›Paper›PMID 25772061›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2015

GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014.

Alexander Heifetz, Gebhard F X Schertler, Roland Seifert, Christopher G Tate, Patrick M Sexton, Vsevolod V Gurevich, Daniel Fourmy, Vadim Cherezov, Fiona H Marshall, R Ian Storer and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. FLRTing Neurons in Cortical Migration During Cerebral Cortex Development.Frontiers in cell and developmental biology · 2020
    Review
  9. Article
  10. In-silico guided discovery of novel CCR9 antagonists.Journal of computer-aided molecular design · 2018
    Article
  11. The Role of G Protein-coupled Receptor Kinases in Cancer.International journal of biological sciences · 2018
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 5 countries.

Alexander HeifetzEvotec (UK) Ltd., 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UK, Alexander.Heifetz@Evotec.com.
Gebhard F X Schertler
Roland Seifert
Christopher G Tate
Patrick M Sexton
Vsevolod V Gurevich
Daniel Fourmy
Vadim Cherezov
Fiona H Marshall
R Ian Storer
Isabel Moraes
Irina G Tikhonova
Christofer S Tautermann
Peter Hunt
Tom Ceska
Simon Hodgson
Mike J Bodkin
Shweta Singh
Richard J Law
Philip C Biggin
Evotec (United Kingdom) · GBBoehringer Ingelheim (Germany) · DEDiamond Light Source · GBETH Zurich · CHHeptares Therapeutics (United Kingdom) · GBInserm · FRMedizinische Hochschule Hannover · DEMRC Laboratory of Molecular Biology · GBOptibrium (United Kingdom) · GBPfizer (United Kingdom) · GBQueen's University Belfast · GBStevenage Bioscience Catalyst · GBUCB Pharma (United Kingdom) · GBUniversity of Oxford · GBVanderbilt University Medical Center · US

Funding

Biotechnology and Biological Sciences Research Council BB/L026287/1Medical Research Council MC_U105197215
6 · The paper itself

Abstract

G-protein coupled receptors (GPCRs) are the targets of over half of all prescribed drugs today. The UniProt database has records for about 800 proteins classified as GPCRs, but drugs have only been developed against 50 of these. Thus, there is huge potential in terms of the number of targets for new therapies to be designed. Several breakthroughs in GPCRs biased pharmacology, structural biology, modelling and scoring have resulted in a resurgence of interest in GPCRs as drug targets. Therefore, an international conference, sponsored by the Royal Society, with world-renowned researchers from industry and academia was recently held to discuss recent progress and highlight key areas of future research needed to accelerate GPCR drug discovery. Several key points emerged. Firstly, structures for all three major classes of GPCRs have now been solved and there is increasing coverage across the GPCR phylogenetic tree. This is likely to be substantially enhanced with data from x-ray free electron sources as they move beyond proof of concept. Secondly, the concept of biased signalling or functional selectivity is likely to be prevalent in many GPCRs, and this presents exciting new opportunities for selectivity and the control of side effects, especially when combined with increasing data regarding allosteric modulation. Thirdly, there will almost certainly be some GPCRs that will remain difficult targets because they exhibit complex ligand dependencies and have many metastable states rendering them difficult to resolve by crystallographic methods. Subtle effects within the packing of the transmembrane helices are likely to mask and contribute to this aspect, which may play a role in species dependent behaviour. This is particularly important because it has ramifications for how we interpret pre-clinical data. In summary, collaborative efforts between industry and academia have delivered significant progress in terms of structure and understanding of GPCRs and will be essential for resolving problems associated with the more difficult targets in the future.

Indexed as

Drug DiscoveryAnimalsComputer SimulationCooperative BehaviorCrystallographyDrug IndustryHumansModels, MolecularReceptors, G-Protein-CoupledUniversitiesReceptors, G-Protein-Coupled

Identifiers

PMID25772061
PMCPMC4495723
OpenAlexW2050218426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.